Colon Cancer
Conditions
Brief summary
Predictive biomarkers are needed to identify those patients with higher risk of recurrence after surgery for colon cancer with curative intent. Our main objective is to determine a metabolite profile in blood plasma from patients operated from colorectal cancer that can be associated with the oncologic outcome and be validated as predictive biomarkers in future studies. A secondary objective is to study the glycolytic metabolism of colon cancer cell lines treated with plasma samples from the same patients. In particular, to validate the increased utilization of lactate by tumor cells as a metabolic substrate using postoperative human samples. Patients with colorectal cancer that have undergone surgical resection will be included. Plasma samples will be obtained before surgery and the 4th day and the 3rd, 6th, 12th, and 18th months after surgery. Metabolic profiles in plasma samples will be determined using a kit that allows the quantification of 180 metabolites by mass spectrometry. A clinical follow up will be maintained for at least 2 years to identify tumor recurrences.
Detailed description
Up to 30-40% of patients operated from colorectal cancer display tumor recurrence. Predictive biomarkers are needed to identify those patients with higher risk of recurrence. Our main objective is to determine a metabolite profile in blood plasma from patients operated from colorectal cancer that can be associated with the oncologic outcome and be validated as prognostic biomarkers in future studies. A secondary objective is to study the glycolytic metabolism of colon cancer cell lines treated with plasma samples from the same patients. In particular, to validate the increased utilization of lactate by tumor cells as a metabolic substrate using postoperative human samples, as it was previously observed by us in vitro using an inflammatory environment in conditions of hypoxia and lack of glucose. Patients with colorectal cancer that have undergone surgical resection will be included. Plasma samples will be obtained before surgery and the 4th day and the 3rd, 6th, 12th, and 18th months after surgery. Metabolic profiles in plasma samples will be determined using a kit that allows the quantification of 180 metabolites by mass spectrometry. Cellular assays will be performed on the SW620 and HT-29 colon cancer cell lines. Cells will be treated with plasma samples and the concentration of lactate and other metabolites will be analyzed in the medium supernatants. A clinical follow up will be maintained for at least 2 years to identify tumor recurrences.
Interventions
PROCEDURESurgery
Segmental resection for colon cancer and anterior resection in patients with rectal cancer
Sponsors
University of Barcelona
Parc de Salut Mar
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Non-metastatic colon and rectal cancer undergoing surgery with curative intent * Patients signed informed consent
Exclusion criteria
* Patients undergoing preoperative chemotherapy and/or radiotherapy * Emergency surgery * Surgical resection R1 or R2 * Patients presenting with other known malignancies for which they are receiving treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease-free survival | 5 years from the date of surgery | Time from the date of surgery to the date of first documentation of recurrence |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Postoperative mortality | 30 days from the date of surgery | — |
| Local recurrence | 5 years from the date of surgery | Tumor associated with surgical site (anastomosis, tumor bed, and mesentery) and confirmed histologically or by imaging. |
| Systemic recurrence | 5 years from the date of surgery | Spread of the disease outside the surgical field to organs such as the liver, lungs, bones, or brain |
| Postoperative intra-abdominal sepsis | 30 days from the date of surgery | Anastomotic leak or intra-abdominal abscess |
| Disease-specific survival | 5 years from the date of surgery | Time from the date of surgery to death by colon cancer |
Countries
Spain
Outcome results
None listed